Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) — Working Capital to Net Assets Ratio
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has a Working Capital to Net Assets ratio of 58.0% as of March 2026. Working capital of €24.30 Billion (current assets of €65.07 Billion minus current liabilities of €40.76 Billion) is measured against net assets of €41.89 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how many days can Guangzhou Baiyunshan Pharmaceutical Hold fund operations to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Working Capital to Net Assets (2013–2025)
This chart shows how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 58.0%, reflecting working capital of €24.30 Billion against net assets of €41.89 Billion EUR. For the complete balance sheet picture, see Guangzhou Baiyunshan Pharmaceutical Hold asset portfolio.
Annual Working Capital to Net Assets for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Guangzhou Baiyunshan Pharmaceutical Hold liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 55.9% | €22.39 Billion | €40.08 Billion | €61.52 Billion | €39.12 Billion | ▲ +6.0 pp |
| 2024 | 49.9% | €18.85 Billion | €37.77 Billion | €57.76 Billion | €38.92 Billion | ▼ -3.9 pp |
| 2023 | 53.8% | €19.75 Billion | €36.68 Billion | €55.98 Billion | €36.24 Billion | ▼ -4.6 pp |
| 2022 | 58.5% | €19.67 Billion | €33.64 Billion | €57.06 Billion | €37.40 Billion | ▼ -7.1 pp |
| 2021 | 65.6% | €20.56 Billion | €31.33 Billion | €52.81 Billion | €32.25 Billion | ▲ +1.3 pp |
| 2020 | 64.4% | €18.15 Billion | €28.21 Billion | €47.40 Billion | €29.24 Billion | ▲ +0.5 pp |
| 2019 | 63.9% | €16.61 Billion | €25.99 Billion | €45.98 Billion | €29.38 Billion | ▼ -5.6 pp |
| 2018 | 69.5% | €16.08 Billion | €23.14 Billion | €43.03 Billion | €26.95 Billion | ▲ +0.8 pp |
| 2017 | 68.7% | €13.23 Billion | €19.26 Billion | €21.50 Billion | €8.27 Billion | ▲ +0.2 pp |
| 2016 | 68.5% | €12.09 Billion | €17.65 Billion | €19.51 Billion | €7.42 Billion | ▲ +34.2 pp |
| 2015 | 34.3% | €2.98 Billion | €8.68 Billion | €9.80 Billion | €6.83 Billion | ▼ -1.6 pp |
| 2014 | 35.8% | €2.84 Billion | €7.92 Billion | €8.92 Billion | €6.08 Billion | ▲ +3.8 pp |
| 2013 | 32.0% | €2.25 Billion | €7.02 Billion | €7.30 Billion | €5.05 Billion | — |